Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 28;10(1):98.
doi: 10.1186/s13045-017-0466-3.

Emerging therapies for breast cancer

Xichun Hu  1   2 , Wei Huang  3 , Minhao Fan  4
Affiliations
Review

Emerging therapies for breast cancer

Xichun Hu et al. J Hematol Oncol. .

Abstract

HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free survival; however, overall survival data are waited. Optimization of chemotherapy and endocrine strategies remains an unmet need. Check point inhibitor-based immunotherapy combined with chemotherapy is a promising field, especially for triple-negative breast cancer.

Keywords: ADC; Breast cancer; CDK4/6 inhibitors; Fulvestrant; Nab-paclitaxel; PARP inhibitors; PD1 and PD-L1 antibodies; SERD.

PubMed Disclaimer

References

    1. Leung BS, Potter AH. Mode of estrogen action on cell proliferation in CAMA-1 cells: II. Sensitivity of G1 phase population. J Cell Biochem. 1987;34(3):213–25. doi: 10.1002/jcb.240340307. - DOI - PubMed
    1. Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res. 1983;43:3998–4006. - PubMed
    1. Sherr CJ. Cancer cell cycles. Science. 1996;274(5293):1672–7. doi: 10.1126/science.274.5293.1672. - DOI - PubMed
    1. Roussel MF, Theodoras AM, Pagano M, Sherr CJ. Rescue of defective mitogenic signaling by D-type cyclins. Proc Natl Acad Sci U S A. 1995;92(15):6837–41. doi: 10.1073/pnas.92.15.6837. - DOI - PMC - PubMed
    1. Jiang H, Chou HS, Zhu L. Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression. Mol Cell Biol. 1998;18(9):5284–90. doi: 10.1128/MCB.18.9.5284. - DOI - PMC - PubMed

MeSH terms